These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16247420)

  • 1. Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation.
    Tauchmanovà L; De Simone G; Musella T; Orio F; Ricci P; Nappi C; Lombardi G; Colao A; Rotoli B; Selleri C
    Bone Marrow Transplant; 2006 Jan; 37(1):81-8. PubMed ID: 16247420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients.
    Chae YS; Kim JG; Moon JH; Kim SN; Lee SJ; Kim YJ; Sohn SK
    Bone Marrow Transplant; 2009 Jul; 44(1):35-41. PubMed ID: 19139732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
    Dane C; Dane B; Cetin A; Erginbas M
    Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors influencing changes in bone mineral density in patients with anorexia nervosa-related osteoporosis: the effect of hormone replacement therapy.
    Legroux-Gerot I; Vignau J; Collier F; Cortet B
    Calcif Tissue Int; 2008 Nov; 83(5):315-23. PubMed ID: 18836675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of vibration therapy on bone mineral density in postmenopausal women with osteoporosis.
    Ruan XY; Jin FY; Liu YL; Peng ZL; Sun YG
    Chin Med J (Engl); 2008 Jul; 121(13):1155-8. PubMed ID: 18710630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy.
    Yao S; McCarthy PL; Dunford LM; Roy DM; Brown K; Paplham P; Syta M; Lamonica D; Smiley S; Battiwalla M; Padmanabhan S; Hahn T
    Bone Marrow Transplant; 2008 Feb; 41(4):393-8. PubMed ID: 17994116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of low-dose cholecalciferol and calcium treatment on posttransplant bone loss in renal transplant patients: a prospective study.
    Sahin G; Yasar NS; Sirmagul B; Bal C; Yalcin AU
    Ren Fail; 2008; 30(10):992-9. PubMed ID: 19016151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
    Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial.
    Otrock ZK; Azar ST; Shamseddeen WA; Habr D; Inati A; Koussa S; Mahfouz RA; Taher AT
    Ann Hematol; 2006 Sep; 85(9):605-9. PubMed ID: 16830143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
    Rodrigues P; Hering FO; Bruna P; Meller A; Afonso Y
    Int J Urol; 2007 Apr; 14(4):317-20. PubMed ID: 17470161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies.
    Tauchmanovà L; Selleri C; Esposito M; Di Somma C; Orio F; Bifulco G; Palomba S; Lombardi G; Rotoli B; Colao A
    Osteoporos Int; 2003 Dec; 14(12):1013-9. PubMed ID: 14517597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
    Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia.
    Gilfillan CP; Strauss BJ; Rodda CP; Bowden DK; Kean AM; Obaid M; Crawford BA
    Calcif Tissue Int; 2006 Sep; 79(3):138-44. PubMed ID: 16969592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of immunosuppression-induced hypogonadism on bone metabolism after heart transplantation].
    Stief J; Sohn HY; Alt A; Uberfuhr P; Theisen K; Stempfle HU
    Dtsch Med Wochenschr; 2004 Jul; 129(31-32):1674-8. PubMed ID: 15273918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease activity and disability but probably not glucocorticoid treatment predicts loss in bone mineral density in women with early rheumatoid arthritis.
    Book C; Karlsson M; Akesson K; Jacobsson L
    Scand J Rheumatol; 2008; 37(4):248-54. PubMed ID: 18612924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic use of zoledronic acid to prevent early bone loss is safe and feasible in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
    Ganguly S; Divine CL; Aljitawi OS; Abhyankar S; McGuirk JP; Graves L
    Clin Transplant; 2012; 26(3):447-53. PubMed ID: 22003964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.